Shares of Medline (NASDAQ:MDLN – Get Free Report) gapped up prior to trading on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $34.09, but opened at $37.37. Medline shares last traded at $37.8190, with a volume of 2,193,313 shares traded.
The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The business had revenue of $7.86 billion during the quarter. Medline had a return on equity of 8.22% and a net margin of 1.84%.
Medline News Roundup
Here are the key news stories impacting Medline this week:
- Positive Sentiment: Medline reported third-quarter EPS of $0.44, above the $0.32 consensus, on $7.86 billion in revenue. Reports also said the company raised its full-year growth outlook. Medline Q3 results
- Positive Sentiment: Several analysts raised price targets and maintained bullish ratings: UBS to $49, Citi to $47, and Leerink Partners to $46; BTIG reaffirmed Buy with a $55 target. These actions signal continued confidence in the stock’s potential. Read More., Read More., Read More., Read More.
- Positive Sentiment: Medline plans to raise prices in 2027 to help offset inflation, and reports cited a $1 billion share-buyback plan—both potential supports for financial performance and shareholder returns. Pricing and Q3 results
- Negative Sentiment: Despite the EPS beat, one report said quarterly profit fell, while Medline reaffirmed its full-year adjusted EBITDA outlook rather than raising it. That may have tempered the positive reaction to the results. Q3 profit and outlook report
- Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to alleged product-quality issues. This is an allegation and investigation announcement, not a finding of wrongdoing, but it could add uncertainty for investors. Investigation announcement
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Medline
Insiders Place Their Bets
In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the transaction, the insider owned 16,453,806 shares in the company, valued at $576,705,900.30. This represents a 11.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 7,948,676 shares of company stock valued at $281,805,137 over the last three months. Corporate insiders own 0.81% of the company’s stock.
Institutional Trading of Medline
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its stake in Medline by 8.4% during the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock worth $506,546,000 after buying an additional 887,240 shares during the last quarter. Banque Pictet & Cie SA increased its holdings in shares of Medline by 2.0% during the third quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company’s stock worth $258,692,000 after buying an additional 142,939 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Medline by 233.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock valued at $222,500,000 after acquiring an additional 3,500,000 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of Medline by 39,404.0% in the first quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock valued at $155,929,000 after acquiring an additional 3,495,136 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Medline by 30,255.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock worth $94,353,000 after acquiring an additional 2,691,529 shares in the last quarter.
Medline Stock Down 1.5%
The firm has a market capitalization of $52.27 billion and a price-to-earnings ratio of 33.35. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. The firm has a fifty day moving average price of $34.68 and a 200 day moving average price of $39.51.
About Medline
Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.
Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.
Featured Articles
- Five stocks we like better than Medline
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
